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Abstract:

Background: An entirely novel antihypertensive strategy incorporates a segment of vein into the arterial circuit using an anastomotic coupler device to restore the Windkessel function that results in an immediate and significant fall in blood pressure (BP). This report presents the first detailed physiological characterization of the effects of the coupler using invasive and non-invasive monitoring.
Methods and Results: A fixed 4mm diameter conduit was created between the right external iliac artery and vein through an endovascular approach. The haemodynamic changes in relation to coupler placement were evaluated with left and right heart catheterisation, pulse wave analysis, oscillometric office BP (OBP) and ambulatory BP (ABP) measurement. The opening of the arterio-venous (AV) coupler immediately leads to a reduction in mean arterial pressure (MAP) of 13% due to a profound reduction in systemic vascular resistance (SVR) by 38% on the table. In tandem there are increases in stroke volume (24%), cardiac output (39%) and heart rate (14%) due to the proximal AV shunt. At 6 months post anastomosis formation, repeat cardiac catheterisation demonstrated greater reductions in SVR (-50%) and MAP (-24%) compared to baseline.
Conclusion: The profound reduction in systemic vascular resistance seen with the coupler has never been previously demonstrated utilising drug or other device therapy for hypertension such as renal denervation. The result confirm the critical role of arterial mechanics in the perpetuation of hypertension and provides substantiation to the recent findings that therapies such as renal denervation work less well in patients with arterial stiffness.

Keywords Blood pressure (BP), Hypertension (HTN), arterio-venous (AV) fistula, coupler, systemic vascular resistance (SVR)
Device-based therapies increase therapeutic options for the treatment of HTN for patients who fail polypharmacy due to adverse reactions or choice. Here we report the physiology related to a device, which uniquely addresses the structural aetiology of HTN.  Creation of a fixed size central AV anastomosis mechanically causes an immediate and significant reduction of BP  ADDIN EN.CITE (1). We present the first detailed haemodynamic findings before and after implantation of the ROX™ Coupler.  
Case: A 74 years old Caucasian female with longstanding isolated systolic HTN complicated by multiple drug intolerances was referred for treatment of her HTN. She could only tolerate liquid furosemide 20 mg daily, which lowered her office BP (OBP) from 220/100 mmHg to 190/90 mmHg. She exhibited features of raised arterial stiffness with increased pulse pressure, pulse wave velocity (PWV) and it was felt that sympathomodulation would not be beneficial for BP control. An AV anastomosis was created using the ROX coupler, inserted in a standard catheterisation lab setting under fluoroscopic guidance via an endovascular approach through the femoral vessels (Fig.1) ADDIN EN.CITE (2). In situ, the coupler creates a fixed calibre 4mm conduit between the external iliac artery and vein transferring 0.8 L/min of blood from the arterial to the venous compartment. The haemodynamic changes in relation to coupler placement were evaluated with left and right heart catheterisation, PWV, OBP and ambulatory BP (ABP) measurement (Table 1). The opening of the AV coupler immediately leads to a large reduction in MAP of 13% due to a profound reduction in SVR by 38% on the table (Fig 2). In tandem there are increases in stroke volume (SV) (24%), CO (39%) and HR (14%) due to the proximal AV shunt. Of note, pulmonary vascular resistance (PVR) was seen to immediately decline (-46%) despite an increase in pulmonary flow possibly due to improved central oxygenation. At 6M-post anastomosis formation, repeat catheterisation demonstrated greater reductions in SVR (-50%) and MAP (-24%) compared to baseline, accompanied by further increase in CO (46%), SV (67%) and PVR (53%). There were also large, immediate (1 day post coupler) and durable (6M post coupler) reductions in OBP and ABP parameters at 6M with no change to the baseline medication regimen and no change in exercise capacity. The reduction in weight of 1kg (2%) suggests that total body volume is largely unchanged following central AV anastomosis.. 
Discussion: The opening of the 4mm, fixed diameter, central AV conduit leads to utilisation of a proximal, low resistance, high compliance central venous segment in parallel with the aorta and results in an immediate and significant reduction in SVR (-38% with coupler opening and -50% at 6M). The lowering of SVR in part arises due to creation of the low resistance parallel circuit. Furthermore the reduction in serum renin/aldosterone post coupler, indicating reduced activation of the renin angiotensin system suggests a sympathoinhibitory component to the mechanism of action. Other haemodynamic and neurohumoral factors likely to facilitate reduction in SVR are mentioned in fig 3. The increase in CO immediately post-coupler (38%) and at 6M (46%) is due in part to coupler mediated venous filling of 0.8 L/min and is also facilitated by the hemodynamic unloading of the left ventricle consequent upon a large reduction in afterload. The reduction and or change in the aortic stress-strain relationship results in lower PWV reducing aortic augmentation. This physiology is in part appreciated in patients receiving peripheral AV fistula for dialysis with a reduction in SVR of 17% soon after fistula formation. ADDIN EN.CITE (3) Antihypertensive drug therapy has disparate effects on haemodynamics depending on drug class used but no single drug therapy has caused reduction in SVR greater than 15%. Furthermore after sympathomodulatory therapy such as RDN, lowering of SVR of only 19% has been demonstrated with ABP reduction of 10/5 mm Hg.(4) The central iliac AV anastomosis is a unique solution to HTN in patients with reduced aortic compliance, a situation where neuro-hormonal interventions would not be anticipated to have substantial impact. The reduction in BP and SVR that we report is immediate and far greater in magnitude that alternative treatment strategies. 
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Table 1. The haemodynamic changes in relation to coupler placement determined by left and right heart catheterisation, pulse wave analysis and oscillometric office BP and ambulatory BP measurement 

Left and Right Heart Catheters	Baseline on table Pre-coupler opening	Immediately post coupler opening	6M F/U	Change from baseline post coupler insertion(% change vs baseline)	Change at 6M FU vs Baseline(% change vs baseline)
Heart Rate (Baseline)	70	80	58	10 (14)	-12 (-17)
Aorta systolic pressure (mm Hg)	240	216	190	-24 (-10)	-50 (-21)
Aorta diastolic pressure (mm Hg)	96	80	69	-16 (-17)	-27 (-28)
MAP (mm Hg)	144	125	109	-19 (-13)	-35 (-24)
LV Systolic Pressure - Mean (mm Hg)	230.0	196	190	-34 (-15)	-40 (-17)
LV Diastolic Pressure - Mean (mm Hg)	19	24	20	5 (26)	1 (5)
RA Pressure - Mean (mm Hg)	6	7	8	1  (17)	2 (33)
RV Systolic Pressure - Mean (mm Hg)	32	34	35	2  (6)	3 (9)
RV Diastolic Pressure - Mean (mm Hg)	3	5	8	2 (67)	5 (167)
PA Systolic Pressure – Mean (mm Hg)	30	33	32	3 (10)	2 (7) 
PA Diastolic Pressure - Mean (mm Hg)	12	13	17	1  (8)	5 (42)
PA Mean Pressure (mm Hg)	18	21	26	3  (17)	8 (44)
PAWP Mean Pressure (mm Hg)	14	18	17	4 (29)	3 (21)
Cardiac Output (Mean) L/min	4.1	5.7	6.0	1.6 (39)	1.9 (46)
Systolic Pressure Variation 	25	6	15	-19 (-76)	-10 (-40)
Stroke Volume	51	63	86	12 (24)	35 (67)
Cardiac Index	2.5	3.4	3.6	0.9 (36)	1.1 (44)
Stroke Volume index	30	38	51	8 (24)	21 (70)
Systemic Vascular Resistance	2693	1661	1346	-1032 (-38)	-1347 (-50)
Pulmonary Vascular Resistance	78	42	119	-36 (-46)	41 (53)
LV Stroke Work	90	92	108	2 (2)	18 (20)
RV Stroke Work	8	12	21	4 (50)	13 (163)
Coronary Artery Perfusion Pressure	82	62	52	-20 (24)	-30 (37)
					
	Baseline	1 Day post coupler	6M post coupler 	Change at Day 1 vs Baseline(% change vs baseline)	Change at 6M vs Baseline(% change vs baseline)
Weight (kg)	60.3	60	59.3	-0.3 (-0.5)	-1 (-2)
Office Blood Pressure 					
Systolic BP (mm Hg)	179	128 (28)	147 (18)	-51 (-28)	-32 (-18)
Diastolic BP (mm Hg)	82	60	61	-18 (-22)	-19 (-23)
HR	73	82	67	9 (12)	-6 (-8)
Ambulatory BP 					
24 hour Systolic BP (mm Hg) 	147 	138 	131 	-9 (-6)	-16 (-11)
24 hour Diastolic BP (mm Hg) 	78 	69 	56 	-9 (12)	-22 (-28)
24 hour MAP (mm Hg) 	103 	94 	83 	-9 (-9)	-20 (-19)
24 hour HR 	72 	75 	68 	3 (4)	-4 (-6)
					
Pulse wave Velocity	Baseline	Day 3	6M FU	Change at Day 3 vs Baseline(% change vs baseline)	Change at 6M vs Baseline(% change vs baseline)
Pulse wave Velocity (m/sec)	12.1	7.8	10.8	-4.3 (-36)	-1.3 (-11)
Augmentation Index	0.43	0.36	0.38	-0.07 (-16)	-0.05 (-12)




Figures

Figure 1A: Arteriovenous coupler and introducer.
The ROX coupler is a self-expanding nitinol stent-like device inserted in the catheterisation laboratory in a procedure lasting 40 minutes.















Figure 1B: Fluoroscopically guided AV Coupler placement.
This results in creation of a fixed caliber central anastomosis between external iliac artery and vein 



Figure 2: Immediate BP reduction with opening of coupler. 
The on table BP reduction is large and immediately follows opening of the anastomosis (verifying technical success of the procedure) and also is reversed with coupler closure.







Figure 3: Central AV anastomosis effects 
Dramatic reduction in invasively measured BP immediately upon opening of the coupler arises due to creation of a parallel low resistance circuit and profound lowering of systemic vascular resistance.








AV coupler

Reduced systemic vascular resistance is primarily mechanical due to parallel low resistance venous circuit, decreased effective arterial volume & improved arterial compliance 

In addition increased tissue oxygenation & increased release of ANP & vasopressin
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Increased cardiac output 
equal to AV fistula flow 
augmented by left ventricular unloading
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